Imagine taking a GLP-1 medication as a simple daily pill—no injections, no refrigeration, taken anytime without food or water restrictions. That's exactly what Eli Lilly's orforglipron promises to deliver.
With FDA submission filed in December 2025 and positive Phase 3 results across multiple trials, orforglipron could be the medication that brings GLP-1 therapy to hundreds of millions of people worldwide who can't access or don't want injectable medications.
đź“‹ Development Status: FDA Submission Filed
Lilly submitted orforglipron to the FDA in December 2025 for obesity treatment
Granted FDA Commissioner's National Priority Review Voucher
Not yet approved for use
Why This Matters
Current GLP-1 medications like Ozempic, Wegovy, and Zepbound are all injectable—and that's a significant barrier for many people:
- Needle phobia—Many people simply won't self-inject
- Cold storage requirements—Injectables need refrigeration, limiting access in many regions
- Supply constraints—Complex manufacturing for injectable peptides limits global supply
- Cost—Injectable GLP-1s are expensive to manufacture and distribute
While oral semaglutide (Rybelsus) exists, it comes with significant restrictions: it must be taken first thing in the morning, with water only, 30+ minutes before eating. This makes it inconvenient for many people.
Orforglipron eliminates these barriers—it's a once-daily pill taken anytime, with or without food.
What Makes Orforglipron Different
| Feature | Orforglipron | Oral Semaglutide (Rybelsus) |
|---|---|---|
| Molecule type | Small molecule (non-peptide) | Peptide (requires absorption enhancer) |
| Food/water restrictions | None | Must take fasting, wait 30+ min to eat |
| Time of day | Any time | Morning only (practically speaking) |
| Manufacturing | Simpler small molecule synthesis | Complex peptide manufacturing |
| Storage | Room temperature | Room temperature |
Current GLP-1 drugs are peptides—short proteins that get destroyed by stomach acid. That's why they're injected or (in the case of Rybelsus) require complex formulation to survive the gut. Orforglipron is a "small molecule" that naturally survives digestion, allowing simple oral delivery.
Clinical Trial Results
ATTAIN-1: Obesity Without Diabetes
Published in New England Journal of Medicine (September 2025), this pivotal trial enrolled 3,127 adults with obesity or overweight with at least one weight-related complication, but without diabetes:
| Dose | Weight Loss (%) | Weight Loss (lbs) |
|---|---|---|
| 6 mg | 7.8% | ~17 lbs |
| 12 mg | 9.3% | ~20 lbs |
| 36 mg | 12.4% | 27.3 lbs |
| Placebo | 2.1% | ~5 lbs |
Beyond weight loss, participants showed significant improvements in:
- Waist circumference
- Systolic blood pressure
- Non-HDL cholesterol
- Triglycerides
- Glycated hemoglobin (A1C)
ATTAIN-2: Obesity With Type 2 Diabetes
This trial specifically studied people with both obesity and type 2 diabetes—a population that typically has more difficulty losing weight:
| Outcome | 36 mg Orforglipron | Placebo |
|---|---|---|
| Weight loss | 10.5% (22.9 lbs) | 2.2% (5.1 lbs) |
| A1C reduction | 1.8% | — |
ATTAIN-MAINTAIN: Switching From Injectables
One of the most important trials asked: Can people maintain weight loss if they switch from injectable GLP-1s to oral orforglipron?
Participants who had previously lost weight on Wegovy or Zepbound were randomized to either orforglipron or placebo for 52 weeks. Results:
- From Wegovy → Orforglipron: Maintained weight loss with only 0.9 kg regain
- From Zepbound → Orforglipron: Maintained weight loss with 5.0 kg regain
- Placebo groups: Regained 9+ kg
This suggests orforglipron could serve as a maintenance option for people who've achieved their weight goals on injectable medications.
Side Effects
The side effect profile is consistent with other GLP-1 medications—primarily gastrointestinal:
| Side Effect | 36 mg Orforglipron | Placebo |
|---|---|---|
| Nausea | 33-36% | 8-10% |
| Diarrhea | 23-27% | 10-15% |
| Vomiting | 23-24% | 4% |
| Constipation | 22-25% | 8-10% |
Most side effects were mild to moderate. Discontinuation rates due to adverse events ranged from 6-11% depending on the trial and dose—comparable to injectable GLP-1s.
Importantly, no liver safety signal was observed—a concern that has affected some other small-molecule drug candidates.
How Does It Compare to Injectables?
The honest answer: weight loss with orforglipron (12.4% at 72 weeks) is somewhat less than with injectable semaglutide (~15%) or tirzepatide (~21%).
However, there are important considerations:
- Convenience tradeoff: Less weight loss may be acceptable if it means taking a simple pill instead of weekly injections
- Access: Many people who can't or won't use injectables could benefit
- Primary care adoption: Pills are easier to prescribe and manage in primary care settings
- Cardiometabolic improvements: Blood pressure, cholesterol, and blood sugar improvements were substantial despite lower weight loss
Global Supply Implications
Perhaps the biggest potential impact of orforglipron is on global access. Lilly has stated:
- Small molecule drugs are simpler and cheaper to manufacture than peptides
- No cold chain storage requirements for distribution
- The company is "confident in its ability to launch orforglipron worldwide without supply constraints"
In a world where injectable GLP-1 shortages have affected millions of patients, this manufacturing advantage could be transformative.
Timeline and Availability
- December 2025: FDA submission filed for obesity
- 2026: Expected FDA submission for type 2 diabetes
- 2026: FDA decision expected (granted National Priority Review Voucher)
If approved, orforglipron would join Wegovy (injectable semaglutide) and Zepbound (injectable tirzepatide) as FDA-approved obesity medications, but as the first convenient, once-daily oral option without restrictions.
What We Don't Know Yet
- Cardiovascular outcomes: No SELECT-style cardiovascular outcomes trial yet for orforglipron
- Long-term data: Trials extend to 72 weeks; longer-term data will come with time
- Pricing: Will it be more affordable than injectable GLP-1s?
- Insurance coverage: Will it be covered better than injectables?
Orforglipron represents a potential game-changer in GLP-1 therapy: a once-daily oral pill that can be taken anytime, without food or water restrictions, showing 12.4% weight loss at the highest dose. While weight loss is somewhat lower than injectable options, the convenience factor could bring effective obesity treatment to millions who currently can't or won't use injections.
With FDA submission filed and National Priority Review status granted, orforglipron could be available in 2026. It may also serve as a maintenance option for people who've lost weight on injectables and want to switch to an oral medication. The simpler manufacturing could also help address global supply constraints that have plagued injectable GLP-1s.
Status: Not yet FDA-approved. Phase 3 trials completed successfully. Currently under FDA review.
Sources
- Eli Lilly. "Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss in ATTAIN-1." Press release. September 2025.
- Wharton S, et al. "Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment." New England Journal of Medicine. 2025.
- Eli Lilly. "Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial (ATTAIN-2)." Press release. August 2025.
- Eli Lilly. "Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins (ATTAIN-MAINTAIN)." Press release. December 2025.
- Weill Cornell Medicine. "Oral GLP-1 Drug Orforglipron Promotes Substantial Weight Loss in Clinical Trial." September 2025.
- Eli Lilly. "What to Know About Orforglipron Oral GLP-1." December 2025.
Currently Available GLP-1 Options
While orforglipron isn't yet available, compare currently approved GLP-1 providers.
Compare Providers →